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EDITORIAL
Racial and ethnic disparities in renal disease
There is no longer any serious doubt that there are seri-
ous disparities in the incidence and prevalence of chronic
kidney disease (CKD) between the white populations of
developed nations and indigenous and migrant groups
either residing within those countries or within the de-
veloping world. Evidence for this was published as long
as a quarter of a century ago [1]. Rather less well known
or acknowledged is the regrettable difference between
these populations in terms of the resources and treat-
ment that are either available or sought. In this issue of
Kidney International, Norris and Agodoa [2] provide a
closer analysis of these disparities. Feehally, in a recent
review published in Kidney International [3], examined
the problem in the context of the successive waves of mi-
gration to Great Britain from the Caribbean in the 1950s
and, subsequently, from South Asia after 1970, while Nor-
ris and Agodoa have largely confined their analysis to the
ethnic and indigenous minority groups living within the
United States. These situations resemble those in Canada
and Australia, where, since white settlement, indigenous
populations have for the most part lived in social and ge-
ographic isolation from the dominant white population
(there are no aboriginal members in the Australian fed-
eral parliament) and in poverty and lamentable health..
Rates of CKD leading to end-stage renal disease (ESRD)
are among the highest in the world among tribal Aus-
tralian aborigines, although in an urban setting the preva-
lence is much less [4], a factor which may be associated
with more racial admixing. In a similar vein, the higher
rates of disease that are found in the first wave of migrants
to a new country may be less apparent in the second gen-
eration who tend to take on the habits and customs of
their adopted country, and who are likely also to become
more prosperous and therefore perhaps are less likely to
be afflicted with the diseases of their forebears.
Somewhat surprisingly, in New Zealand, where the
Maori/Polynesian population has lived in a much more
integrated fashion with the white population, patient
survival following the instigation of renal replacement
therapy (RRT) does not differ from that found in the
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aboriginal population of Australia. There has, therefore,
to be a suspicion that the medical model of health [5]
which has served nephrologists so well in the develop-
ment of dialysis and renal transplantation does not func-
tion so well in these populations, where the demands of
the treatment process mean forced removal from their
homes and communities into unfamiliar, even hostile sur-
roundings for lengthy periods of time. In the case of
transplantation, the requirement for long-term immune
suppression places many of these patients at a high risk
for opportunistic infection, and this and uncertain compli-
ance with treatment regimens often underpins the poorer
survival data found in these groups and tends to influence
the decision making of those charged with the responsibil-
ity of allocating kidneys for transplantation in a negative
fashion, especially in the live donor setting.
Because of the many confounding biases, it is difficult
to separate the important associations of CKD: to state
with any confidence whether it is a consequence of class,
poverty, excessive smoking, poor health care and edu-
cation, or the many other deprivations which, for many
indigenous and migrant groups, have become a way of
life. Furthermore, correction of these afflictions doesn’t
fall within the ambit of medicine, although nephrologists
may be considered to have a duty to raise these issues
with appropriate authorities
Norris and Agodoa draw attention to the more rapid
progression of renal disease found in ethnic and indige-
nous minorities [6]. Two factors that may well be responsi-
ble for this phenomenon are poor control of diabetes and
hypertension. In the Native American population, and
both in the New Zealand Maori and the Australian abo-
riginal population, diabetic nephropathy has been des-
ignated as the most common cause of CKD, although
this diagnosis has usually been made without histologic
confirmation. These populations were noted to be free
of diabetes prior to World War II. Rapid acculturation
to western habits and the adoption of some of the worst
dietary features, together with a much more sedentary
lifestyle than hitherto, have contributed to this: a particu-
larly brutal example of an environmental hazard grafted
on to genetic susceptibility. Data from the Pima have
shown how the offspring of marriages between subjects
who both display evidence of CKD (or proteinuria) are
more likely to themselves suffer from subsequent renal
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disease. It is hardly surprising, therefore, that diabetic
nephropathy shows a rising incidence.
Hypertensive kidney disease appears to have a partic-
ular predilection for people of African descent. It is gen-
erally accepted that the malignant phase of hypertension
characterized by the presence of fibrinoid necrosis of the
resistance vessels can cause primary renal disease, but the
nephrologic community remains divided as to whether
essential hypertension can affect the kidney similarly, or
whether much renal hypertension is more a consequence
of the underlying disease process, while accepting that
it can certainly contribute to progression. South African
nephrologists see a lot of malignant hypertension, and
it appears as the most common cause of ESRD in the
African population of that country. Poorer control of hy-
pertension would be an unsurprising feature of renal dis-
ease in migrant groups who have less access to medical
services in many areas, and would be expected to hasten
progression, especially in the case of diabetic nephropa-
thy. Attention to these two risk factors which, although
often clinically silent, are more susceptible to diagnosis
than CKD, has the potential to have a beneficial effect
on disease progression. Neither Norris and Agodoa, nor
Feehally makes much reference to the situation regarding
CKD in developing nations. Indeed, there are very little
published data on the subject. There are still countries
in which there are no nephrologists, and no facilities for
dialysis and transplantation other than on an insured or
fee paying basis. The outcomes of treatment within such
establishments tend not to be published in any publicly
available literature. CKD rates have not been calculated,
and dialysis access cannot really be used as a proxy for
them because RRT is available to only a tiny proportion
of the population. Screening programs are superficially
an attractive proposition as a first step toward defining
the extent of CKD, but they need to be sequential if its
incidence is to be calculated, and, from an ethical view-
point, they risk being regarded as academic exercises,
unless they are accompanied by treatment regimens. In
these settings there is such a lack of resources that RRT
for all is not a practical proposition, and treatment pro-
grams may well have to rely on local initiatives, using
the most cheaply available drugs to manage diabetes and
hypertension [7]. Successive publications since 1993 [8]
have clearly shown that angiotensin-converting enzyme
(ACE) inhibitor and, subsequently, angiotensin II recep-
tor blocking agents are significantly effective singly or
in combination both in reducing proteinuria and slowing
the progression of renal disease, as well as controlling
hypertension. Only one such study is being specifically
conducted in an indigenous population [9] other than the
AASK study [10], both tending to show stabilization of
proteinuria. Even when out of patent, they remain ex-
pensive agents, and there are important safety concerns
regarding their use in young fertile women, who might
constitute up to 40% of the cases being considered for
treatment. Unless they become widely available as a re-
sult of generous gifting, they may not be usable in devel-
oping world settings.
From whatever standpoint one views the problem of
CKD in disadvantaged groups and developing nations,
the problems are going to be difficult to resolve, and will
require nephrologists to work long and hard in consort
with many other professional groups.
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